Five of the world’s biggest drugs companies have agreed to slash the price of
their anti-HIV drugs in developing countries by 85 per cent following sustained
pressure from health agencies, Third World governments and patient groups
(New Scientist, 29 April, p 14).
One of the companies, Glaxo Wellcome, is
cutting the price of triple drug therapy from $16 to $2 a day. But
pressure groups have warned that even at these prices, poverty and a lack of
health infrastructure in poor countries will mean the benefits are limited.
To continue reading, today with our introductory offers
Advertisement
More from New Scientist
Explore the latest news, articles and features
Popular articles
Trending New Scientist articles
1
Where, when and how to watch the 2026 solar eclipse
2
If you aren't terrified by this heatwave, you should be
3
Our verdict on The Selfish Gene: An unpopular piece of popular science
4
We鈥檝e uncovered a master gene that switches on human development
5
The race to understand how and when Thwaites glacier will collapse
6
Europe鈥檚 heatwave is the hottest and most humid ever
7
Can home batteries help save the climate and save you money?
8
Most portable air conditioners suck 鈥 but there's an easy fix
9
Woman with Alzheimer's starts conversing again after taking psilocybin
10
The best sci-fi novel in 2026 so far 鈥 plus 6 other great reads
